Detalhe da pesquisa
1.
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
J Clin Oncol
; 40(28): 3239-3245, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947804
2.
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Blood Adv
; 8(10): 2400-2404, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38531062